1975 French citizen

Yannick Marchalant Born in Bayonne, France, the 09/09/1975 French citizen Professional address: Central Michigan University Health Profession Buildin...
Author: Harvey Wheeler
8 downloads 0 Views 155KB Size
Yannick Marchalant Born in Bayonne, France, the 09/09/1975 French citizen

Professional address: Central Michigan University Health Profession Building HP 2181 Mount Pleasasnt, MI, 48859, USA

Academic Experience: August 2014 to present: Assistant professor, Department of Psychology, Central Michigan University. “Neuroinflammation and cannabinoids in normal and pathological aging” May 2014 to July 2014: Research Ingeneer, Cerimed, INSERM U 1076, Assistance Publique des Hôpitaux de Marseille led by Dr Benjamin Guillet, Marseille France. :”Nano Targeted molecular imaging of angiogenesis in prostate cancer” March 2010 to April 2014: Researcher (IRG Marie-Curie 2010-2014), UMR 7259 CNRS-Aix-Marseille University led by Dr Michel Khrestchatisky, Marseille, France. : « Endocannabinoids, proteinase and Neuroinflammation in the prevention of Alzheimer’s disease». Dec. 2008 to Feb. 2010: Research Assistant Professor, The Ohio State University, Columbus, OH, USA. : « Influence of endocannabinoids on normal and pathological aging, particularly on neuroinflammation and neurogenesis ». Dec. 2005 to Nov. 2008: Post-doctoral position, The Ohio State University, Columbus, OH, USA, Dr. Gary L. Wenk: « Role of the endocannabinoid system in the regulation of inflammation in aged rodents. » Apr. 2004 to Nov. 2005: Post-doctoral position, Division of Neural Systems, Memory & Aging, University of Arizona, Tucson, AZ, USA, Dr. Gary L. Wenk: « Role of inflammation in a transgenic mouse and aging rodent model of Alzheimer’s disease.» 2004: Ph.D. Biology, Medicine and Health Care, option Molecular and Cellular Aspects of Biology, University of Caen, France: Dissertation Title: Physiological mechanisms of cerebral activation: Modulatory role of the galaninergic and the ascending cholinergic system in the relationship between cerebral blood flow, metabolism and neuronal activity in the rat whiskers stimulation paradigm. 2000: M.Sc. in Cell Biology option Neurosciences, University of Caen, France. 1998: B.Sc. in Biochemistry option Immunology and Neurosciences, University of Caen, France.

Teaching Experience: Lecturer: 2015: Lecturer, 3 credit course, PSY 387 “Behavioral Neuroscience”, department of psychology, Central Michigan University, MI, USA. 2015: Lecturer, 3 credit course, PSY 587 “physiological psychology”, department of psychology, Central Michigan University, MI, USA. 2014-2015: Lecturer, 3 credit course, PSY 687 “physiological foundations”, department of psychology, Central Michigan University, MI, USA. 2012: Lecturer, 6 credit course, one semester, on “psychology of Learning and Memory”, department of psychology, Aix-Marseille University, France. 2010: Lecturer, 3 credit course, one semester, on “psychology of Learning and Memory” psych 600, The Ohio State University, Columbus, OH, USA. 2006-2009: Lecturer: “Barbiturates and Benzodiazepines” and “The opioid system” in course “Drugs, Brain and Behavior,” Department of Psychology, The Ohio State University, Columbus, OH, USA. 2009: Lecturer: “History of use and abuse of amphetamines” in graduate course “behavioral neuroscience”, Department of Neuroscience, The Ohio State University, Columbus, OH, USA. 2008: Lecturer: “Dementia and Aging” in graduate course “behavioral neuroscience”, Department of

Neuroscience, The Ohio State University, Columbus, OH, USA. 2006-2007: Lecturer: “Learning and Memory” in course “Introduction to Psychobiology,” Department of Psychology, The Ohio State University, Columbus, OH, USA. 2005: Lecturer: “Barbiturates and Benzodiazepines” in course “Drugs, Brain and Behaviour,” Department of Psychology, University of Arizona, Tucson. AZ, USA. 2001: Lecturer 3 credit course, 1 semester, department of Psychology, University of Caen, France.

Grants and Awards: 2015-2016: PI: Early Career Grant (CMU, 20 000$), “deciphering the role of neuroinflammation in the early events of AD »

2010-2014: PI: Contrat Marie-Curie IRG (International Reintegration Grant, 100 000€), “Targeting Inflammation and Neurogenesis using cannabinoids to delay the onset of Alzheimer’s disease”. 2006-2007: PI: Grant from Merz pharmaceuticals (200 000$). Study of memantine (Namenda®) in various models of neuroinflammation in young and aged rats. 2008-2013: Co-PI: National Institute of Aging, RO1 AG030331, “Aging microglia-neuronal communication” (1 400 000$) PI Gary Wenk 2004-2008: Co-PI: National Institute of Aging, RO1 AG10546, “aging vulnerability to inflammatory processes” (1 250 000$) PI Gary Wenk 2013-2014: Participant: France Alzheimer fondation (50 000€) « role of MT5-MMP on the prevention of Alzheimer’s disease » 2012-2015: Participant: ANR (650 000€) « MMP-12 as an early marker and therapeutic target in Alzheimer’s disease progression » 2011-2013: Participant: Ligue Européeen Contre la Maladie d’Alzheimer (LECMA, 80 000€), MMPs and TIMPs in Alzheimer’s disease pathogenesis. 2009-2012: Participant: ANR (700 000€) “Functional interplay between the TIMP/MMP and the LRP-1 system in Alzheimer’s disease: new therapeutic targets” 2005: Grant from the Philippe Foundation, Inc. (4 000$): Role of the endocannabinoid system in the regulation of inflammation in a rodent model of Alzheimer disease. 2003: Grant from the Lilly Institute (5 000€): Influence of the cholinergic basalocortical pathway on the relationships between cerebral blood flow, metabolism and neuronal activity. 2002: Grant from the French Pharmacological Society (13 000€): Influence of the cholinergic basalocortical pathway on the relationships between cerebral blood flow, metabolism and neuronal activity: pharmacological study.

Advisory Positions and Society Memberships: Reviewer for: Journal of pharmacology and Experimental Therapeutics, Journal of Applied physiology, Journal of Neuroinflammation, Learning and Memory, Molecular Neurobiology, Neurobiology of Aging, Mutation research, Neuropsychiatric disease and treatment, Neuroscience, Journal of Alzheimer’s Disease, Journal of Neuroscience Methods, British Journal of Pharmacology, Neuropharmacology. Grants’ Reviewer for: The Alzheimer’s Association (USA) Health Research Council of New Zealand Polish academy of science Agence Nationale Pour la Recherche (ANR, France)

Society Membership Society For Neuroscience (2004-today) International Cannabinoid Research Society (2006-2007; 2014-today) International Society on Aging and Disease (2015-today) Michigan Chapter of the Society for Neuroscience (2015-today) PhD Examination: Riffat Tanveer (2013), 'Endocannabinoids and Notch-1 signaling in an in vitro model of Alzheimer’s disease and with normal aging', Trinity college, Dublin, Ireland Simran Maggo (2013), ‘Neurophysiological role of statins’, Otago University, Otago, New Zealand.

Media coverage of Research Television: ABC news 2008, Columbus affiliates for the implication of my research in the treatment of Alzheimer’s disease (USA). Journal, Magazine, newspapers: Marijuana and Alzheimer’s disease coverage by: Time Magazine, Msn.com, Health Day, Reuters, Bloomberg, Scientific American, Wired, WebMD, CBS News, Nature, Boston globe, New York Daily News (and Newspapers in England, Spain, Brazil, Germany, India, Australia…) Publications

1. Baranger K., Marchalant Y., Bonnet A.E., Crouzin N., Carrete, A., Paumier J.M., Py N.A., Bernard A., Bauer C., Charrat E., Moschke K., Seiki, M, Vinges M., Lichtenthaler S.F., Checler F., Khrestchatisky M., Rivera S.: MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mous mondel of Alzheimer’s disease. Cell and Molecular Life Sciences, In press 2. Bonnet A.E., Marchalant Y. Potential therapeutical contributions of the endocannabinoid system towards aging and Alzheimer’s disease. Aging and Disease, (2015) 6:400-5 3. Py N.A., Bonnet A.E., Bernard A., Marchalant Y., Charrat E, Checler F, Khrestchatisky M, Baranger K, Rivera S. Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer's disease: evidence for a pro-amyloidogenic role of MT1MMP. Front Aging Neurosci. (2014) 6:247 4. Marchalant Y., Brownjohn P., Bonnet A., Kleffmann T., Ashton J.: Antibody sensitivity does not imply specificity: the cannabinoid CB2 receptor. . J Histochemistry and Cytochemistry (2014) 62: 395-404

5. Brothers H.M., Bardou I., Hopp S.C., Marchalant Y., Kaercher R.M., Turner S.M., Mitchem

M.R., Kigerl K., Wenk G.L.: Time-dependent compensatory responses to chronic neuroinflammation in hippocampus and brainstem: The potential role of glutamate neurotransmission. J Alzheimers Dis Parkinsonism (2013) 3: 110.

6. Crouzin N., Baranger K., Cavalier M., Marchalant Y., Cohen-Solal C., Roman F., Khrestchatisky M., Rivera S., Feron F., Vignes M. Area-specific alterations of synaptic plasticity in the 5xFAD mouse model of Alzheimer’s disease: Dissociation between somatosensory cortex and hippocampus PlosOne (2013) 8: e74667.

7. Bardou I., DiPatrizio N., Brothers H.M., Kaercher R.M., Baranger K., Mitchem M., Hopp S.C., Wenk G.L. & Marchalant Y.: Pharmacological manipulation of cannabinoid neurotransmission reduces neuroinflammation associated with normal aging. Health (2012) 4: 679-84.

8. Marchalant Y., Baranger K., Wenk G.L., Khrestchatisky M., Rivera S.: Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention? J Neuroinflammation. (2012) 9:10.

9. Brothers H.M, Marchalant Y., Wenk G.L.: Caffeine attenuates lipopolysaccharide-induced neuroinflammation. Neurosci Lett. (2010) 480:97-100

10.Marchalant Y., Brothers H.M., Wenk G.L.: Cannabinoid Agonist win-55,212-2 partially restores neurogenesis in the aged rat brain. Molecular psychiatry, (2009) 14: 1068-1071

11.Marchalant Y., Brothers H.M., Norman G.H., Karelina K., Devries A.C., Wenk G.L.: Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. Neurobiol. Dis. (2009) 34(2): 300-307

12.Marchalant Y., Cerbai F., Brothers H.M., Wenk G.L.: Cannabinoid receptor stimulation is antiinflammatory and improves memory in old rats. Neurobiology of aging (2008) 29(12): 1894-1901.

13.Marchalant Y., Brothers, H.M., Wenk G.L: Neuroinflammation in young and aged rats: influence of endocannabinoids and caffeine. Journal of neuroimmunology (2008) vol. 197 (2): 168

14.Marchalant Y., Brothers, H.M., Wenk G.L.: Inflammation and aging: Can endocannabinoids help? . Biomedecine and Pharmacotherapy (2008) vol. 62 (4), 212-7

15.Marchalant Y., Rosi S, Wenk GL: Anti-inflammatory property of the cannabinoid agonist WIN55212-2 in a rat model of chronic brain inflammation. Neuroscience. (2007) 144(4):1516-22.

16.Barbelivien A, Vaussy C, Marchalant Y, Maubert E, Bertrand N, Beley A, Roussel S, Mackenzie

ET, Dauphin F.: Degeneration of the basalocortical pathway from the cortex induces a functional increase in galaninergic markers in the nucleus basalis magnocellularis of the rat. J Cereb Blood Flow Metab. (2004) 24(11):1255-66.

17.Gsell W., De Sadeleer C., Marchalant Y., MacKenzie E.T., Schumann P., Dauphin F. The use of cerebral blood flow as an index of neuronal activity in functional neuroimaging : experimental and pathophysiological considerations. (2000) J. Chem. Neuroanat. 20 (3-4) 215-224 Submitted or in preparation:

Book Chapter: Wenk, G.L. & Marchalant, Y. Neuropharmacology. In: G.G. Berntson & J.T. Cacioppo, (Eds.) Handbook of Neuroscience for the Behavioral Sciences, John Wiley & Sons.

Invited Presentations: § § § § § § § § §

Neuroinflammation in normal and pathological aging, 2014 Central Michigan University, USA. Neuroinflammation in normal and pathological aging, 2014 Buck Institute, CA, USA. Neuroinflammation in normal and pathological aging, 2014 NIA, Baltimore, MD, USA. Cannabinoids in neuroinflammation and neurogenesis: From normal ageing to Alzheimer’s disease models. ICAD meeting, 2011, Paris France. Coffee and marijuana may prevent Alzheimer’s and Parkinson’s disease, Society for Neuroscience, 2009, Washington DC, USA Influence du système cannabinoide sur la neuroinflammation et le vieillissement cérébral, 2008, Université de Bordeaux, France Influence du système cannabinoide sur la neuroinflammation et le vieillissement cérébral, 2008, Centre Cyceron, Caen, France Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. International cannabinoid research society meeting, 2007, Saint Sauveur, QC, Canada Anatomical and functional evidence for the existence of an innervation of rat cerebrovascular vessels by galanin. European Congress of Cytometry Applied to Pathology, 2001, Caen, France.

Poster Presentation: 2015:



Taylor, TN, Marchalant Y. Deciphering the role of neuroinflammation in the early events of Alzheimer’s disease. MiSFN chapter meeting, CMU, MI, USA



Taylor, TN, Marchalant Y. Deciphering the role of neuroinflammation in the early events of Alzheimer’s disease. SRCEE, CMU, MI, USA

2014:



Bonnet A, Baranger K, Py N, LAcassagne E, Jabes F, Marchalant Y, Molino Y, Lichtenthaler S, Dive V, Rivera, S, Khrestchatisky M. Involvment of MMP-12 in neurovascular damages, Inflammation and amyloidogenesis in Alzheimer’s disease. FENS, Milan, Italy

2013:



Marchalant Y, Baranger K, Bonnet A, Py N, Khrestchatisky M et Rivera, S. Preventive Approach to Delay Inflammatory-related Phenomenons in Alzheimer´s Disease Using 5xFAD Mice: Role of Cannabinoids and Matrix Metalloproteinases. AD/PD conference, Florence, Italy 2012:



Baranger K, Marchalant Y, Py N, Bonnet A, Druon-Bauer C, Bernard A, Girard S, Roman F, Seiki M, Checler F, Khrestchatisky M et Rivera, S. MT5-MMP, un nouvel acteur dans la maladie d’Alzheimer. 6ème Colloque SFBBM « Protéolyse cellulaire » Clermont-Ferrand, France.



Rivera S, Baranger K, Py N, Girard S, Bernard A, Bonnet A, Charrat E, Seiki M, Roman F, Marchalant Y, Khrestchatisky M. Membrane-type 5-matrix metalloproteinase (MT5-MMP), a new player in Alzheimer’s disease. FENS meeting, Barcelona, Spain.



Khrestchatisky M, Baranger K, Py N, Girard S, Bernard A, Bonet A, Charrat E, Seiki M, Roman F, Marchalant Y and Rivera S. Membrane-type 5-matrix metalloproteinase (MT5-MMP), a new player and target in Alzheimer’s disease. Second Annual Conference of COST Action ECMNET “Brain Extracellular Matrix in Health and Disease” Barcelona, Spain.



Py N, Baranger K, Bonnet A, Marchaland Y, Bernard A, Charrat E, Khrestchatisky M and Rivera S. Age-dependent upregulation of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) in the 5xFAD mice model of Alzheimer's disease. FENS, Barcelona, Spain. 2011:



Bardou I, Brothers HM, Hopp SC, Emerman A, Marchalant Y, Wenk GL. The effects of cannabinoids on neuroinflammation, neurogenesis and memory in aged rats. Society For Neuroscience meeting, Washington DC, USA.



Weinhard L, Baranger K, Py N, Girard S, Bernard A, Checler F, Roman F, Khrestchatisky M, Rivera S, Marchalant Y. Cannabinoids in neuroinflammation and neurogenesis : From normal ageing to Alzheimer’s disease models. AD/PD meeting, Barcelona Spain.



Baranger K, Marchalant Y, Bernard A, Py N, Weinhard L, Charrat E, Girard S, Roman F, Khrestchatisky M, Rivera S Matrix metalloproteinases (MMPs) and their physiological tissue inhibitors (TIMPs) in the 5xFAD mice model of Alzheimer’s disease. AD/PD meeting, Barcelona Spain.



Baranger K, Py N, Sevalle J, Bernard A, Charrat E, Marchalant Y, Checler F, Khrestchatisky M, Rivera S. Interplay between the metalloproteinase/TIMP system and APP/Abeta metabolism. AD/PD meeting, Barcelona Spain. 2010:



Marchalant Y, Brothers HM, Di Patrizio N, Kaercher R, Mitchem M, Wenk GL Effects of chronic FAAH inhibition using URB597 on neuroinflammation and neurogenesis in aged rats. Society for Neuroscience meeting, San Diego, California.



Brothers HM, Kaercher R, Mitchem M, Turner S, Marchalant Y, Wenk GL Time-dependant recovery from a neuroinflammation-induced spatial memory deficit corresponds with increased SNAP25 expression in the hippocampus. Society for Neuroscience meeting, San Diego, California. 2009:



Marchalant Y, Brothers HM, Mitchem M, Kaercher R, Turner S, Wenk GL. Cannibinoids versus Endocannabinoids in aging rats: which could benefit more to neuroinflammation and neurogenesis? Society for Neuroscience meeting, Chicago, Illinois.



Brothers HM, Kaercher R, Turner S, Marchalant Y, Wenk GL (2009.10). Chronic neuroinflammation reproduces characteristics of Parkinson’s disease in the substantia nigra, locus ceruleus, and raphe nucleus. Society for Neuroscience meeting, Chicago, Illinois.



Wenk GL, Del Soldato P, Brothers HM, Marchalant Y (2009.10). Hydrogen sulfide-donatingdiclofenac and -L-DOPA effectively reduce neuroinflammation in aged rats. Society for Neuroscience meeting, Chicago, Illinois.



Marchalant Y, Brothers HM, Mitchem M, Kaercher R, Turner S, Wenk GL. Cannabinoids or Endocannabinoids: what benefits on neuroinflammation and neurogenesis? Gordon research conference, university of New england. 2008:



Marchalant Y, Brothers HM, L. Burgess, Wenk GL. Endocannabinoid effects on neuroinflammation and neurogenesis in aged rats, Society for Neuroscience meeting, Washington DC.



Marchalant Y, Brothers HM, Wenk GL. Role of endocannabinoides and Memantine on neuroinflammation, memory and neurogenesis in aged rats. International conference on Alzheimer’s disease, July 2008, Chicago, USA.



Brothers H.M., Cerbai F., Marchalant Y., Wenk G.L. Regional susceptibility to inflammation: neuronglia interactions in the hippocampus and substantia nigra and rescue by the NMDA antagonist Memantine. Poster presented at the ICAD meeting, Chicago, Illinois.



Wenk G.L., Brothers H.M., Marchalant Y. Neuron-Glia intercommunication during neuroinflammation associated with Alzheimer's disease and other neurodegenerative disorders. Poster presented at the ICAD meeting, Chicago, Illinois.



Cerbai F, Brothers H.M., Marchalant Y., Giovannini M.G., Wenk G.L. Role of CD200 in neuron-glia intercommunication during inflammation. Poster presented at the FENS meeting, Geneva, Switzerland



Wenk GL., Brothers H, Marchalant Y.: Neuron-glia intercommunication during neuroinflammation associated with Alzheimer’s disease and other neurodegenerative disorders. International Behavioral Neuroscience society meeting, June 2008, St Thomas, Virgin Islands.



Marchalant Y, Brothers H, Wenk GL. Neuroinflammation in young and aged rats: Influence of endocannabinoides and caffeine Neuroimmunology symposium, March 2008, Dublin, Ireland. 2007:



Marchalant Y, Brothers H, Cerbai F, Wenk GL. Endocannabinoids receptors effects on neuroinflammation and memory in aged rats. Neuropharmacolgy conference, November 2007, San diego, USA.



Marchalant Y, Brothers H, Cerbai F, Wenk GL. Endocannabinoids receptors effects on neuroinflammation and memory in aged rats. Society for Neuroscience meeting, November 2007, San diego, USA .



Brothers H, Marchalant Y, Cerbai F, Wenk GL. The effects of the adenosine receptor antagonist caffeine upon neuroinflammation: Implications for Alzheimer's and Parkinson's disease. Society for Neuroscience meeting, November 2007, San diego, USA



Marchalant Y, Cerbai F, Brothers H, Wenk GL. Cannabinoid receptor stimulation is antiinflammatory and improves memory in old rats. Ohio Society for Neuroscience chapter meeting, April 2007, Columbus, OH, USA.



Brothers H.M., Marchalant Y., Cerbai F., Wenk G.L. The effects of the adenosine receptor antagonist caffeine upon neuroinflammation: Implications for Alzheimer's and Parkinson's disease. Poster presented at the SfN Central Ohio Chapter meeting, Columbus, Ohio 2006:



Marchalant Y, Cerbai F, Brothers H, Wenk GL. Endocannabinoids agonist effects on inflammation and aging in rats. Society for Neuroscience meeting, october 2006, Atlanta, USA.



Cerbai F, Marchalant Y, Brothers H, Wenk GL. Do endocannabinoids regulate the MAP Kinase pathway on inflammation and aging? Society for Neuroscience meeting, october 2006, Atlanta, USA.



Brothers H, Marchalant Y, Cerbai F, Wenk GL. The effects of the adenosine receptor antagonist caffeine upon neuroinflammation: Implications for Alzheimer's and Parkinson's disease. Society for Neuroscience meeting, october 2006, Atlanta, USA.



Marchalant Y, Rosi S, Wenk GL: Anti-Inflammatory Actions of the Endocannabinoid System in a Rodent Model of Chronic Neuroinflammation. International conference on alzheimer’s disease meeting, July 2006, Madrid, Spain. 2005:



Marchalant Y, Rosi S, Wenk GL: Anti-inflammatory property of the cannabinoid agonist WIN55212-2 in a neuroinflammation rat model of Alzheimer disease. Society for Neuroscience meeting, November 2005, Washington DC, USA.



Rosi S; Vazdarjanova A, Ramirez-Amaya V, Marchalant Y, Worley P.F, Barnes C.A, Wenk G.L. : the consequences of neuroinflammation upon hippocampal immediate early gene expression can be reversed by the NMDA receptor antagonist Memantine. Society for Neuroscience meeting, November 2005, Washington DC, USA. 2003:



Marchalant Y., Barbelivien A., MacKenzie E.T., Dauphin, F.: Anatomical and functionnal evidence for the existence of an innervation of rat cerebrovascular vessels by galanin. Brain03 congress, july 2003, calgary, Canada. 2002:



Marchalant Y., Barbelivien A., Maubert E., Divoux D., MacKenzie E.T., Dauphin F. : Contribution à la mise en évidence d’une innervation galaninergique des vaisseaux sanguins cérébraux intraparenchymateux chez le rat. Annual meeting of the LARC-Neurosciences, Caen, October 2002 .



Marchalant Y., Barbelivien A., Maubert E., Divoux D., MacKenzie E.T., Dauphin F. : contribution à la mise en evidence d’une innervation galaninergique des vaisseaux sanguins cerebraux intraparenchymateux chez le rat. Annual meeting of on the IFR 47 (medical imagery and health care), Caen, April 2002.